Macitentan
- Generic Name
- Macitentan
- Brand Names
- Opsumit
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20Br2N6O4S
- CAS Number
- 441798-33-0
- Unique Ingredient Identifier
- Z9K9Y9WMVL
- Background
Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. It was first approved by the FDA in 2013. Macitentan differs from its predecessor bosentan due to its lower risk of hepatotoxicity.
- Indication
Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
- Associated Therapies
- -
Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Actelion
- Target Recruit Count
- 550
- Registration Number
- NCT00667823
- Locations
- 🇺🇸
Santa Barbara Cottage Hospital, Santa Barbara, California, United States
🇺🇸Emory University Hospital - McKelvey Center for Lung Transplantation & Pulmonary Vascular Disease, Atlanta, Georgia, United States
🇺🇸Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.